In vitro treatment with retinoids decreases bcl-2 protein expression and enhances dexamethasone-induced cytotoxicity and apoptosis in multiple myeloma cells

European Journal of Haematology

Volumn 62, Issue 3, 1999, Pages 143-148

  Tosi, Patrizia ^a,b   Pellacani, Annalisa ^a   Visani, Giuseppe ^a   Ottaviani, Emanuela ^a   Ronconi, Sonia ^a   Zamagni, Elena ^a   Benni, Monica ^a   Cavo, Michele ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Apoptosis; BCL 2; Dexamethasone; Multiple myeloma; Retinoids

Indexed keywords

ALITRETINOIN; DEXAMETHASONE; ISOTRETINOIN; PROTEIN BCL 2; RETINOIC ACID; RETINOID;

APOPTOSIS; ARTICLE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 0033061083     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01736.x     Document Type: Article

References (33)

1. GOBBI M, CAVO M, SAVELLI GA, et al. Prognostic factors and survival in multiple myeloma. Analysis of ninety-one cases treated by melphalan and prednisone. Haematologica 1980;65:437-443.
2. BERGSAGEL DE. Chemotherapy of myeloma In: MALPAS JS, BERGSAGEL DE, KYLE RA, eds. Myeloma: biology and management. Oxford: Oxford University Press, 1995;273-306.
3. ALEXANIAN R, BARLOGIE B, DIXON D. High-dose glucocorticoid treatment of resistant myeloma. Ann Int Med 1986;105:8-11.
4. GREGORY WM, RICHARDS MA, MALPAS JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992;10:334-342.
5. CAVO M, BENNI M, GOZZETTI A, TURA S. The role of haematopoietic stem cell supported myeloablative therapy for the management of multiple myeloma. Baillière's Clin Haematol 1995:795-813.
6. GAHRTON G, TURA S, LJUNGMAN P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991;325:1267-1273.
7. DIMOPOULOS M, KANTARJIAN H, ESTEY E, ALEXANIAN R. 2-chlorodeoxyadenosine in the treatment of multiple myeloma. Blood 1992;79:1626.
8. KRAUT EH, CROWLEY JJ, GREVER MR. Phase II of fludarabine phosphate in multiple myeloma. Invest New Drugs 1990;8:199-206.
9. NGUYEN MH, TREON SP, BROITMAN SA. In vitro studies in support of taxol for the treatment of multiple myeloma. Blood 1994;suppl 1:179a.
10. MILLER H, LEONG T, KHANDEKAR J, GREIPP P, KYLE R, KRAM J. Paclitaxel as the initial treatment of multiple myeloma (MM). An Eastern Cooperative Oncology Group (ECOG) study. Blood 1995;suppl 1:188a.
11. LUTZKY J, VUJICIC M, YAMANISHI DT, BHALLA K. Antiproliferative effects of all-trans retinoic acid (tRA) and 9-cis retinoic acid (9-cisRA) on human lymphoid cell lines. Proc Am Assoc Cancer Res 1993;34:292.
12. OGATA A, NISHIMOTO N, SHIMA Y, YOSHIZAKI K, KISHIMOTO T. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Blood 1994;84:3040-3046.
13. SIDDELL N, TAGA T, HIRANO T, KISHIMOTO T, SAXON A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down regulation of IL-6 receptors. J Immunol 1991;146:3809-3814.
14. NIESVIZKY R, SIEGEL DS, BUSQUETS X, et al. Hypercalcaemia and increased interleukin-6 levels induced by all-trans retinoic acid in patients with multiple myeloma. Br J Haematol 1995;89:217-218.
15. MUSTO P, FALCONE A, SAJEVA MR, D'ARENA G, BONINI A, CAROTENUTO M. All-trans retinoic acid for advanced multiple myeloma. Blood 1995;85:3769-3770.
16. PALUMBO A, BATTAGLIO S, NAPOLI P, et al. Retinoic acid inhibits the growth of human myeloma cells in vitro. Br J Haematol 1995;89:555-560.
17. CHEN YH, DESAI P, SHIAO RT, LAVELLE D, HALEEM A, CHEN J. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: sinergy through modulation of interleukin-6 autocrine loop at multiple sites. Blood 1996;87:314-323.
18. MUSTO P, SAJEVA MR, SANPAOLO G, D'ARENA G, SCALZULLI PR, CAROTENUTO M. All-trans retinoic acid in combination with α-interferon and dexamethasone for advanced multiple myeloma. Haematologica 1997;82:354-356.
19. YUH YS, THOMPSON EB. Glucocorticoid effect on oncogene/growth gene expression in human T lymphoblastic leukemic cell line CCRF-CEM. Specific c-myc RNA suppression by dexamethasone. J Biol Chem 1989;264:10904-10910.
20. MIYASHITA T, REED LC. BCL-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992;52:5407-5411.
21. HAMILTON MS, BARKER HF, BALL J, DREW M, ABBOTT SD, FRANKLIN IM. Normal and neoplastic human plasma cells express bcl-2 antigen. Leukemia 1991;5:768-771.
22. CHOU TC, TALALAY P. Quantitative analysis of dose - effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzym Regul 1984;22:27-55.
23. NICOLETTI I, MIGLIORATI G, PAGLIACCI MC, GRIGNANI F, RICCARDI C. A rapid and simple method for measuring of thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991;139:271-279.
24. AIELLO A, DELIA D, BORRELLO MG, et al. Flow cytometric detection of the mitochondrial BCL-2-protein in normal and neoplastic human lymphoid cells. Cytometry 1992;13:502-509.
25. SCUDIERO D, SHOEMAKER RH, PAUL K, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988;48:4827-4833.
26. MOMPARLER RR. In vitro systems for evaluation of combination chemotherapy. Pharmacol Ther 1980;8:21-35.
27. TU Y, XU F, LIU J, et al. Upregulated expression of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin, etoposide, and hydrogen peroxide. Blood 1996;88:1895-1812.
28. LIPPMAN SM, MEYSKENS FL. Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmacol Ther 1989;40:107-122.
29. HONG WK, LIPPMAN SM, ITRI LM, et al. Prevention of primary tumors with isotretinoin in squamous-cell carcinoma of head and neck. N Engl J Med 1990;323:795-799.
30. TALLMAN MS, ANDERSEN JW, SCHIFFER CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-1028.
31. COHEN JJ, DUKE RC. Glucocorticoid activation of a calcium-dependand endonuclease in thymocyte nuclei leads to cell death. J Immunol 1984;132:38-42.
32. LEVY Y, LABAUME S, COLOMBEL M, BROUET JC. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. Clin Exp Immunol 1996;104:167-172.
33. ALNEMRI ES, FERNANDES TF, HALDAR S, CROCE CM, LITWACK G. Involvement of BCL-2 in glucocorticoid-induced apoptosis of human pre-B leukemias. Cancer Res 1992;52:491-495.